These data suggest that alternative mechanisms of leukocyte trafficking to the gut may compensate for the absence of CCR5 signaling in IBD patients with this mutation, and conversely that the benefits of maraviroc therapy may be restricted to IBD patients with a functional CCR5 gene. This evidence concerns the gene CCR5 and inflammatory bowel disease.